The various insulin analogs (what Novo-Nordisk calls “modern insulins”) are steadily gaining market share at the expense of ordinary insulin. A tweaked formulation of ordinary insulin, even if it works, is not exactly a winning business idea, IMO.
The reason the analogs are gaining market share is because they were engineered to be either fast acting (lispro, aspart, Glulisine) or long acting (Glargine insulin, Detemir insulin), thus have advantage over regular human insulin. If human insulin can be modified to become ultra fast, it wouldn't be a problem because it wasn't human insulin itself, rather its profile for loss of market share.
In addition, BIOD's ultra fast insulin is tweak on regular human insulin, HALO's ultra fast insulin program is for both regular human insulin and insulin analogs in combination with PH20 hyaluronidase enzyme.
Market Data 
Markets 
AI
